Carlos Vicente-Gutierrez

Carlos Vicente-Gutierrez

Auto-generated profile, based on publicly available information

Carlos Vicente-Gutierrez

Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DJDaniel Jimenez-Blasco
Daniel Jimenez-Blasco
ABArnau Busquets-Garcia
Arnau Busquets-Garcia
EHEtienne Hebert-Chatelain
Etienne Hebert-Chatelain
RSRoman Serrat
Roman Serrat
CVCarlos Vicente-Gutierrez
Carlos Vicente-Gutierrez
GMGiovanni Marsicano
Giovanni Marsicano

4 February 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
CVCarlos Vicente-Gutierrez
Carlos Vicente-Gutierrez
NBNicoló Bonora
Nicoló Bonora
VBVeronica Bobo-Jimenez
Veronica Bobo-Jimenez
DJDaniel Jimenez-Blasco
Daniel Jimenez-Blasco
ILIrene Lopez-Fabuel
Irene Lopez-Fabuel
JBJuan Bolanos
Juan Bolanos

27 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ILIrene Lopez-Fabuel
Irene Lopez-Fabuel
Marina Garcia-MaciaMarina Garcia-Macia
Marina Garcia-Macia
CBCostantina Buondelmonte
Costantina Buondelmonte
OBOlga Burmistrova
Olga Burmistrova
NBNicolo Bonora
Nicolo Bonora
JBJuan Bolanos
Juan Bolanos
CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children.CLN7/MFSD8gene encodes a lysosomal membrane glycoprotein, but the biochemical processes affected by CLN7-loss of function are unexplored thus preventing development of potential treatments. Here, we found, in theCln7∆ex2mouse model of CLN7 disease, that failure in autophagy causes accumulation of structurally and bioenergetically impaired neuronal mitochondria. In vivo genetic approach reveals elevated mitochondrial reactive oxygen species (mROS) inCln7∆ex2neurons that mediates glycolytic enzyme PFKFB3 activation and contributes to CLN7 pathogenesis. Mechanistically, mROS sustains a signaling cascade leading to protein stabilization of PFKFB3, normally unstable in healthy neurons. Administration of the highly selective PFKFB3 inhibitor AZ67 inCln7∆ex2mouse brain in vivo and in CLN7 patients-derived cells rectifies key disease hallmarks. Thus, aberrant upregulation of the glycolytic enzyme PFKFB3 in neurons may contribute to CLN7 pathogenesis and targeting PFKFB3 could alleviate this and other lysosomal storage diseases.

9 January 2023 in Journal of Neurochemistry
Verified
Journal Article
Open access
JCJoão Victor Cabral‐Costa
João Victor Cabral‐Costa
CVCarlos Vicente‐Gutiérrez
Carlos Vicente‐Gutiérrez
JAJesus Agulla
Jesus Agulla
RLRebeca Lapresa
Rebeca Lapresa
JEJohn W. Elrod
John W. Elrod
AKAlicia Kowltowski
Alicia Kowltowski
Intracellular Ca2+ concentrations are strictly controlled by plasma membrane transporters, the endoplasmic reticulum, and mitochondria, in which Ca2+ uptake is mediated by the mitochondrial calcium uniporter complex (MCUc), while efflux occurs mainly through the mitochondrial Na+/Ca2+ exchanger (NCLX). RNAseq database repository searches led us to identify the Nclx transcript as highly enriched in astrocytes when compared with neurons. To assess the role of NCLX in mouse primary culture astrocytes, we inhibited its function both pharmacologically or genetically. This resulted in re‐shaping of cytosolic Ca2+ signaling and a metabolic shift that increased glycolytic flux and lactate secretion in a Ca2+‐dependent manner. Interestingly, in vivo genetic deletion of NCLX in hippocampal astrocytes improved cognitive performance in behavioral tasks, whereas hippocampal neuron‐specific deletion of NCLX impaired cognitive performance. These results unveil a role for NCLX as a novel modulator of astrocytic glucose metabolism, impacting on cognition. image

27 January 2020 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
CVCarlos Vicente-Gutiérrez
Carlos Vicente-Gutiérrez
DJDaniel Jiménez-Blasco
Daniel Jiménez-Blasco
RQRubén Quintana-Cabrera
Rubén Quintana-Cabrera

1 May 2021 in Redox Biology
Verified
Journal Article
Open access
CVCarlos Vicente-Gutierrez
Carlos Vicente-Gutierrez
NBNicolo Bonora
Nicolo Bonora
DJDaniel Jimenez-Blasco
Daniel Jimenez-Blasco
ILIrene Lopez-Fabuel
Irene Lopez-Fabuel
GBGeorgina Bates
Georgina Bates
JBJuan Bolanos
Juan Bolanos
Cells naturally produce mitochondrial reactive oxygen species (mROS), but the in vivo pathophysiological significance has long remained controversial. Within the brain, astrocyte-derived mROS physiologically regulate behaviour and are produced at one order of magnitude faster than in neurons. However, whether neuronal mROS abundance differentially impacts on behaviour is unknown. To address this, we engineered genetically modified mice to down modulate mROS levels in neurons in vivo. Whilst no alterations in motor coordination were observed by down modulating mROS in neurons under healthy conditions, it prevented the motor discoordination caused by the pro-oxidant neurotoxin, 3-nitropropionic acid (3-NP). In contrast, abrogation of mROS in astrocytes showed no beneficial effect against the 3-NP insult. These data indicate that the impact of modifying mROS production on mouse behaviour critically depends on the specific cell-type where they are generated.